Next quarter’s earnings estimate for 2410 is -HK$0.33 with a range of -HK$0.33 to -HK$0.33. The previous quarter’s EPS was ―. 2410 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 2410 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2410 is -HK$0.33 with a range of -HK$0.33 to -HK$0.33. The previous quarter’s EPS was ―. 2410 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 2410 has Performed in-line its overall industry.
Deutsche Bank Starts TYK Medicines (2410:HK) at BuyDeutsche Bank analyst Cyrus Ng initiates coverage on TYK Medicines (2410:HK) with a Buy rating and a price target of HK$31.60.
Deutsche Bank Starts TYK Medicines (2410:HK) at BuyDeutsche Bank analyst Cyrus Ng initiates coverage on TYK Medicines (2410:HK) with a Buy rating and a price target of HK$31.60.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -25.20% per trade.
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -12.90% per trade.
Copying Cyrus Ng's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.40% per trade.
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -39.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
2410 Analyst Recommendation Trends
Rating
May 25
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
total
1
In the current month, 2410 has received 1Buy Ratings, 0Hold Ratings, and 0Sell Ratings. 2410 average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
2410 Stock Forecast FAQ
What is HK:2410’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:2410’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:2410, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TYK Medicines, Inc. Class H a Buy, Sell or Hold?
TYK Medicines, Inc. Class H has a consensus rating of Moderate Buy, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is TYK Medicines, Inc. Class H’s share price target?
Currently, no data Available
What do analysts say about TYK Medicines, Inc. Class H?
TYK Medicines, Inc. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of TYK Medicines, Inc. Class H?
To buy shares of HK:2410, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.